ELVN · CIK 0001672619 · operating
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule kinase inhibitors for oncology indications. The company's pipeline focuses on two lead candidates: ELVN-001, a small molecule kinase inhibitor in Phase 1 trials for chronic myeloid leukemia (CML), and ELVN-002, a central nervous system penetrant and irreversible HER2 inhibitor in Phase 1 development for non-small cell lung cancer and other HER2-driven solid tumors. Both programs represent the company's core approach to cancer treatment through targeted molecular inhibition.
As a clinical-stage entity, Enliven has not yet commercialized approved therapeutics and operates primarily as a research and development organization. The company does not currently generate product revenue. The company maintains a lean operational structure with 65 full-time employees based in Boulder, Colorado. Enliven is incorporated in Delaware and trades on the Nasdaq under the ticker ELVN.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.89 | $-1.89 | +6.0% | |
| 2023 | $-2.01 | $-2.01 | -3450.0% | |
| 2022 | $0.06 | $0.06 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |